Hosted a virtual key opinion leader (KOL) event on November 20, 2024 featuring Abhishek Ray, MD (University Hospitals) and Andrew Webb, PharmD, BCCCP (Massachusetts General Hospital), who discussed ...

Labcorp Holdings Inc. leverages strategic moves like the Fortrea spin-off and Invitae acquisition to drive growth. Read more ...

In connection with the offering, David Liu, a Senior Analyst at Velan Capital, was appointed to Edesa's Board of Directors, ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced ...

Replimune Group (REPL) has disclosed a new risk, in the Share Price & Shareholder Rights category. Replimune Group faces a range of material risks ...

Five industry heavyweights shared their top emergency management strategies with Newsweek during a virtual event on February 13.

What would happen? What actions would be taken on and around Canadian farms? And how can we prevent that scenario from ...

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Recent research from Chatham Financial indicates where companies face exposures and how they’re mitigating the risk.